Cellectis (CLLS) analyst forecast and price target
Analyst forecast
Consensus of 7 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Initiated Coverage | Overweight | $9.00 | May 28, 2026 |
| Citizens | Maintained | Market Outperform | $8.00 | Apr 14, 2026 |
| Clear Street | Initiated Coverage | Buy | $9.00 | Dec 23, 2025 |
| Barclays | Maintained | Overweight | $8.00 from $4.00 | Oct 17, 2025 |
| Barclays | Maintained | Overweight | $4.00 from $5.00 | May 13, 2025 |
| Barclays | Maintained | Overweight | $5.00 from $7.00 | Nov 5, 2024 |
| Oppenheimer | Maintained | Outperform | $10.00 from $11.00 | Jun 12, 2024 |
| JMP Securities | Maintained | Market Outperform | $6.00 | May 31, 2024 |
| JMP Securities | Maintained | Market Outperform | $6.00 | Nov 1, 2023 |
| Oppenheimer | Maintained | Outperform | $11.00 | Aug 8, 2023 |
| JMP Securities | Maintained | Market Outperform | $6.00 | Aug 7, 2023 |
Frequently asked questions
Is CLLS a buy, sell, or hold?
Analysts covering Cellectis currently average a Buy rating: 6 buy, 1 hold and 0 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on CLLS?
On May 28, 2026, Barclays initiated coverage of Cellectis at Overweight with a price target of $9.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.